Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2024-04-08 | Amended | $42,292,450 | $739,670 | Equity Only | 06b | SEC link |
| 2024-03-11 | Amended | $41,552,780 | $2,067,260 | Equity Only | 06b | SEC link |
| 2024-02-12 | Amended | $39,485,520 | $504,560 | Equity Only | 06b | SEC link |
| 2024-01-09 | Amended | $38,980,960 | $18,799,648 | Equity Only | 06b | SEC link |
| 2023-12-11 | Amended | $20,181,312 | $629,595 | Equity Only | 06b | SEC link |
| 2023-11-13 | Amended | $19,551,717 | $2,405,789 | Equity Only | 06b | SEC link |
| 2023-10-13 | Amended | $17,145,928 | $6,551,460 | Equity Only | 06b | SEC link |
| 2023-09-12 | Amended | $10,594,468 | $8,785,498 | Equity Only | 06b | SEC link |
| 2023-08-11 | New | $1,808,970 | $1,808,970 | Equity Only | 06b | SEC link |
| 2019-04-05 | Amended | $11,435,000 | $645,000 | Equity Only | 06b | SEC link |
| 2019-02-13 | New | $10,790,000 | $10,790,000 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Mark Baum | Director |
| John Berdahl | Director |
| Andrew Boll | Director |
| Larry Dillaha | Director, Executive |
| Gregory Madison | Director, Executive |
| Brad Osborne | Executive |